Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients

Area of Science:

• Immunology
• Infectious Diseases
• Transplantation

Background:

• Solid organ transplant (SOT) recipients are highly vulnerable to severe outcomes from coronavirus disease-2019 (COVID-19).
• Untreated COVID-19 in SOT recipients leads to significant hospitalization, intensive care unit (ICU) admission, and mortality.
• Timely diagnosis is critical for initiating effective therapeutic interventions.

Purpose of the Study:

• To review and outline management strategies for COVID-19 in SOT recipients.
• To highlight the importance of early diagnosis and therapeutic interventions.
• To discuss treatment options for both mild-to-moderate and severe/critical COVID-19 in this population.

Main Methods:

• This is a review article.
• The authors synthesized current literature on COVID-19 management in SOT recipients.
• Strategies discussed include diagnosis, therapeutics for different disease severities, and immunomodulation.

Main Results:

• Early administration of therapeutics like remdesivir, ritonavir-boosted nirmatrelvir, or neutralizing monoclonal antibodies can prevent disease progression in mild-to-moderate cases.
• For severe and critical COVID-19, intravenous remdesivir combined with immunomodulation is recommended.
• Effective management strategies are vital to reduce morbidity and mortality.

Conclusions:

• Prompt diagnosis and targeted treatment are essential for managing COVID-19 in SOT recipients.
• A multi-faceted approach involving antivirals, monoclonal antibodies, and immunomodulation improves outcomes.
• Continued research and adherence to guidelines are necessary to optimize care for this high-risk group.